The Sleep After Breast Cancer (ABC) Study

This study, called "The Sleep After Breast Cancer (ABC) Study," is looking at how sleep changes for people with breast cancer during their treatment. Researchers want to understand why some people sleep poorly and how things like stress, social support, and where you live might affect your sleep. They will also see how sleep affects biological aging and inflammation. You might be able to join if you are at least 18 years old, have Stage I to III hormone receptor-positive breast cancer, and have finished your primary surgery but haven't started chemotherapy or radiation. The study aims to enroll 100 participants and will measure your total sleep duration and self-reported sleep quality over about 9 months.

Study design
This is an observational study, meaning no new treatments are given. It plans to include 100 participants.
What's involved
You would provide cheek swab, saliva, and hair samples, wear a wrist sleep tracking device, and complete surveys. Your medical records would also be reviewed.
Compensation
Not stated in the trial record.
Follow-up
Your sleep duration and quality will be measured through study completion, an average of 9 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07341503

The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients

Recruiting
Not specifiedAges 18+Observational
Ohio State University Comprehensive Cancer Center
~100 participants
Updated 2026-01-14 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Total sleep duration
Measured over Through study completion, an average of 9 months
+1 more outcome measured
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Breast Carcinoma
Hormone Receptor-Positive Breast Carcinoma
1 sites across 1 states
Ohio1
  • Electra Paskett, MSPH, PhD, FAACR · PRINCIPAL_INVESTIGATOR · Ohio State University Comprehensive Cancer Center
The Ohio State University Comprehensive Cancer Center
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

\* Age \>= 18 years old at time of breast cancer diagnosis
Stage I to III breast cancer diagnosis
Hormone receptor positive breast cancers
Post primary surgery, before chemotherapy/radiation therapy begins
No known evidence of breast cancer recurrence (local or distant) or second, primary cancer
No prior history of new other malignancy since their breast cancer diagnosis (other than non-melanoma skin cancer)
Able to speak, understand and read English
Cognitively able to complete the study requirements
Ability to access medical records from treating hospital

Exclusion

\* Stage IV or metastatic breast cancer
Not cognitively able to provide informed consent
Not willing to provide informed consent
  • Total sleep durationThrough study completion, an average of 9 months

    Will report descriptive statistics of the sample characteristics using counts and percentages or means and standard deviations. Actigraphy from the sleep watch (GENEActiv device) will be scored and analyzed using validated algorithms within the Activeinsights software (Activinsights, UK). Daily and weekly summaries of sleep statistics will be averaged to generate person-level data for analysis at each time point. a paired t-test to compare T1 sleep duration (pre-treatment) to T3 (treatment completion) sleep duration using SAS PROC POWER.

  • Self-reported sleep quality (PROMIS)Through study completion, an average of 9 months

    Sleep quality (as measured by the PROMIS) will be considered as a continuous variable and categorized into 'poor quality' if patients have a score of \>= 5 and 'good quality' if \< 5 points. Locally weighted scatterplot smoothing will be used to estimate a smooth trend through the sleep data points (sleep duration, sleep quality). Generalized linear mixed models will be used to examine changes in sleep over time (treatment through survivorship).